Duloxetine for Perimenopausal Depression

This study has been completed.
Eli Lilly and Company
Information provided by (Responsible Party):
University of Arizona
ClinicalTrials.gov Identifier:
First received: March 9, 2007
Last updated: July 5, 2012
Last verified: July 2012
Recently, antidepressants have been explored as a class of medications to treat major depression in the context of perimenopause, as well as the somatic symptoms of perimenopause (such as hot flashes). Duloxetine (Cymbalta) is one of the newer antidepressants approved for the treatment of Major Depressive Disorder (MDD). Therefore, the current study is designed to assess the efficacy of duloxetine in a sample of women who are perimenopausal and meet criteria for MDD. We will assess impact on MDD and perimenopausal symptoms.

Condition Intervention Phase
Major Depressive Disorder
Drug: Duloxetine
Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Duloxetine for Perimenopausal Depression

Resource links provided by NLM:

Further study details as provided by University of Arizona:

Primary Outcome Measures:
  • Reduction of the initial HAM-D by 50% or more at week 9 of the trial [ Time Frame: 9 Weeks ] [ Designated as safety issue: No ]
  • Reduction of the HAM-D score to less than or equal to 7 at week 9 [ Time Frame: 9 Weeks ] [ Designated as safety issue: No ]
  • Change of CGI score achievement to "very much improved" or "much improved" at week 9 [ Time Frame: 9 Weeks ] [ Designated as safety issue: No ]
  • A 50% decrease in the GCS at week 9. [ Time Frame: 9 Weeks ] [ Designated as safety issue: No ]

Enrollment: 7
Study Start Date: February 2007
Study Completion Date: June 2008
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Duloxetine
    During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
  Show Detailed Description


Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Women age 40 years old or older.
  • Perimenopausal symptoms of at least 3 months duration, including irregular periods and/or hot flashes.
  • Minimum score of 15 on the Hamilton Rating Scale for Depression (17-item).
  • Subjects must be able to be treated on an outpatient basis.
  • Subjects must be able to provide written informed consent.

Exclusion Criteria:

  • Subjects presently taking antidepressant medication.
  • Subjects currently using hormone replacement therapy.
  • Subjects who are pregnant.
  • Subjects who have hepatic disease.
  • Other Axis I disorders, except Generalized Anxiety Disorder or Panic Disorder.
  • "Uncontrolled" narrow angle glaucoma.
  • Known hypersensitivity to duloxetine or any of the inactive ingredients.
  • Treatment with a monoamine oxidase inhibitor (MAOI) within 14 days of study drug administration or potential need to use an MAOI during the study or within 5 days of discontinuation of study drug.
  • Presence of psychotic symptoms.
  • History of mania or hypomania.
  • Hamilton Rating Scale for Depression (HAM-D) suicide item score > 2.
  • End stage renal disease or severe renal impairment.
  • Abnormal uterine bleeding that has not been evaluated by a gynecologist (heavy or prolonged uterine bleeding, menstrual periods occurring more frequently than every 3 weeks, bleeding after sexual intercourse, spotting between periods).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00517985

United States, Arizona
Women's Mental Health Program; University of Arizona; Department of Psychiatry
Tucson, Arizona, United States, 85724
Sponsors and Collaborators
University of Arizona
Eli Lilly and Company
Principal Investigator: Kathy W Smith, M.D. University of Arizona: Department of Psychiatry
  More Information

Responsible Party: University of Arizona
ClinicalTrials.gov Identifier: NCT00517985     History of Changes
Other Study ID Numbers: F1JUSX026 
Study First Received: March 9, 2007
Last Updated: July 5, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by University of Arizona:
perimenopausal depression
major depressive disorder

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Behavioral Symptoms
Mental Disorders
Mood Disorders
Duloxetine Hydrochloride
Antidepressive Agents
Dopamine Agents
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Peripheral Nervous System Agents
Physiological Effects of Drugs
Psychotropic Drugs
Sensory System Agents
Serotonin and Noradrenaline Reuptake Inhibitors

ClinicalTrials.gov processed this record on May 25, 2016